About the Authors
- Frank Bloos
-
Affiliations Deptartment of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Jena, Germany, Center for Sepsis Control & Care, Jena University Hospital, Jena, Germany
- Svea Sachse
-
Affiliation Jena University Hospital, Institute of Medical Microbiology, Jena, Germany
- Andreas Kortgen
-
Affiliations Deptartment of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Jena, Germany, Center for Sepsis Control & Care, Jena University Hospital, Jena, Germany
- Mathias W. Pletz
-
Affiliation Divison of Gastroenterology, Hepatology and Infectious Diseases, Jena University Hospital, Jena, Germany
- Marc Lehmann
-
Current address: Moldiax GmbH, Jena, Germany
Affiliation SIRS-Lab GmbH, Jena, Germany
- Eberhard Straube
-
Affiliation Jena University Hospital, Institute of Medical Microbiology, Jena, Germany
- Niels C. Riedemann
-
Affiliation Deptartment of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Jena, Germany
- Konrad Reinhart
-
Affiliations Deptartment of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Jena, Germany, Center for Sepsis Control & Care, Jena University Hospital, Jena, Germany
- Michael Bauer
-
* E-mail: Michael.Bauer@med.uni-jena.de
Affiliations Deptartment of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Jena, Germany, Center for Sepsis Control & Care, Jena University Hospital, Jena, Germany
Competing Interests
KR and ES are minimal shareholders of SIRS-Lab GmbH. FB received a travel grant from SIRS-Lab GmbH. MB received consulting fees from SIRS-Lab GmbH. ML was employee of SIRS-Lab GmbH during the conduct of the study, where he had the scientific responsibility for VYOO. ML is now director of Moldiax GmbH, where he has no competing interest regarding this study. SIRS-Lab GmbH has supplied the VYOO®-Kits and personnel to run the PCR. SIRS-Lab GmbH has also financed a prospective study which took place after this study was completed. The study goals and feasibility issues have been discussed with SIRS-Lab GmbH during the preparation phase of the study. ES holds a patent for the LOOXTER technique where prokaryotic DNA can be enriched in a way that a simple PCR protocol (VYOO) can detect such DNA. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: FB KR MB. Performed the experiments: SS. Analyzed the data: FB AK MP. Contributed reagents/materials/analysis tools: ML. Wrote the paper: FB AK NR MB. Interpretation of PCR and blood culture results: ES SS. Organization of PCR setup and interpretation of PCR results: ML. Patient recruitment: FB NR KR. Clinical arbitrators: AK MP.